288 related articles for article (PubMed ID: 36628844)
1. Mucosal immune response after the booster dose of the BNT162b2 COVID-19 vaccine.
Azzi L; Dalla Gasperina D; Veronesi G; Shallak M; Maurino V; Baj A; Gianfagna F; Cavallo P; Dentali F; Tettamanti L; Maggi F; Maffioli LS; Tagliabue A; Accolla RS; Forlani G
EBioMedicine; 2023 Feb; 88():104435. PubMed ID: 36628844
[TBL] [Abstract][Full Text] [Related]
2. Mucosal immune response in BNT162b2 COVID-19 vaccine recipients.
Azzi L; Dalla Gasperina D; Veronesi G; Shallak M; Ietto G; Iovino D; Baj A; Gianfagna F; Maurino V; Focosi D; Maggi F; Ferrario MM; Dentali F; Carcano G; Tagliabue A; Maffioli LS; Accolla RS; Forlani G
EBioMedicine; 2022 Jan; 75():103788. PubMed ID: 34954658
[TBL] [Abstract][Full Text] [Related]
3. Vaccination and Omicron BA.1/BA.2 Convalescence Enhance Systemic but Not Mucosal Immunity against BA.4/5.
Diem G; Jäger M; Dichtl S; Bauer A; Lass-Flörl C; Reindl M; Wilflingseder D; Posch W
Microbiol Spectr; 2023 Jun; 11(3):e0516322. PubMed ID: 37098903
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the systemic and mucosal immune response induced by COVID-19 and the BNT162b2 mRNA vaccine for SARS-CoV-2.
Nickel O; Rockstroh A; Wolf J; Landgraf S; Kalbitz S; Kellner N; Borte M; Pietsch C; Fertey J; Lübbert C; Ulbert S; Borte S
PLoS One; 2022; 17(10):e0263861. PubMed ID: 36256664
[TBL] [Abstract][Full Text] [Related]
5. Serum neutralization of SARS coronavirus 2 Omicron sublineages BA.1 and BA.2 and cellular immune responses 3 months after booster vaccination.
Alidjinou EK; Demaret J; Corroyer-Simovic B; Vuotto F; Miczek S; Labreuche J; Goffard A; Trauet J; Lupau D; Dendooven A; Huvent-Grelle D; Podvin J; Dreuil D; Faure K; Deplanque D; Bocket L; Duhamel A; Sobaszek A; Hober D; Hisbergues M; Puisieux F; Autran B; Yazdanpanah Y; Labalette M; Lefèvre G
Clin Microbiol Infect; 2023 Feb; 29(2):258.e1-258.e4. PubMed ID: 36257549
[TBL] [Abstract][Full Text] [Related]
6. Neutralization of Omicron subvariants BA.1 and BA.5 by a booster dose of COVID-19 mRNA vaccine in a Japanese nursing home cohort.
Itamochi M; Yazawa S; Inasaki N; Saga Y; Yamazaki E; Shimada T; Tamura K; Maenishi E; Isobe J; Nakamura M; Takaoka M; Sasajima H; Kawashiri C; Tani H; Oishi K
Vaccine; 2023 Mar; 41(13):2234-2242. PubMed ID: 36858871
[TBL] [Abstract][Full Text] [Related]
7. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
Front Immunol; 2022; 13():863554. PubMed ID: 35711445
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the mucosal and systemic antibody responses in Covid-19 recovered patients with one dose of mRNA vaccine and unexposed subjects with three doses of mRNA vaccines.
Liu S; Tsun JGS; Fung GPG; Lui GCY; Chan KYY; Chan PKS; Chan RWY
Front Immunol; 2023; 14():1127401. PubMed ID: 36793736
[TBL] [Abstract][Full Text] [Related]
9. SARS-CoV-2-Neutralizing Humoral IgA Response Occurs Earlier but Is Modest and Diminishes Faster than IgG Response.
Takamatsu Y; Omata K; Shimizu Y; Kinoshita-Iwamoto N; Terada M; Suzuki T; Morioka S; Uemura Y; Ohmagari N; Maeda K; Mitsuya H
Microbiol Spectr; 2022 Dec; 10(6):e0271622. PubMed ID: 36219096
[TBL] [Abstract][Full Text] [Related]
10. Immunological responses and adverse reactions of the heterologous second booster dose of BNT162b2 after two-dose CoronaVac for COVID-19 vaccination in healthcare workers of Faculty of Medicine, Naresuan University.
Makanut S; Wangteeraprasert A; Jitpewngam W; Ngoenkam J; Pongcharoen S
Vaccine; 2023 Jun; 41(29):4335-4340. PubMed ID: 37301707
[TBL] [Abstract][Full Text] [Related]
11. Serum and Salivary IgG and IgA Response After COVID-19 Messenger RNA Vaccination.
Gorochov G; Ropers J; Launay O; Dorgham K; da Mata-Jardin O; Lebbah S; Durier C; Bauer R; Radenne A; Desaint C; Vieillard LV; Rekacewicz C; Lachatre M; Parfait B; Batteux F; Hupé P; Ninove L; Lefebvre M; Conrad A; Dussol B; Maakaroun-Vermesse Z; Melica G; Nicolas JF; Verdon R; Kiladjian JJ; Loubet P; Schmidt-Mutter C; Dualé C; Ansart S; Botelho-Nevers E; Lelièvre JD; de Lamballerie X; Kieny MP; Tartour E; Paul S
JAMA Netw Open; 2024 Apr; 7(4):e248051. PubMed ID: 38652471
[TBL] [Abstract][Full Text] [Related]
12. Correlation between anti-S IgG and neutralizing antibody titers against three live SARS-CoV-2 variants in BNT162b2 vaccine recipients.
Higashimoto Y; Kozawa K; Miura H; Kawamura Y; Ihira M; Hiramatsu H; Suzuki R; Haga K; Takai-Todaka R; Sawada A; Katayama K; Yoshikawa T
Hum Vaccin Immunother; 2022 Nov; 18(6):2105611. PubMed ID: 36094467
[TBL] [Abstract][Full Text] [Related]
13. Effects of Omicron Infection and Changes in Serum Antibody Response to Wild-Type, Delta, and Omicron After a Booster Dose With BNT163b2 Vaccine in Korean Healthcare Workers.
Lim SH; Kim HJ; Kim SH; Choi SH; Kim B; Kim JY; Ji YS; Kim T; Choo EJ; Jung JC; Moon JE; Kim CK; Park SK; Yun J
J Korean Med Sci; 2023 Apr; 38(13):e103. PubMed ID: 37012688
[TBL] [Abstract][Full Text] [Related]
14. Persistence of immunity against Omicron BA.1 and BA.2 variants following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-dose AZD1222 vaccination.
Assawakosri S; Kanokudom S; Chansaenroj J; Suntronwong N; Auphimai C; Nilyanimit P; Vichaiwattana P; Thongmee T; Duangchinda T; Chantima W; Pakchotanon P; Srimuan D; Thatsanatorn T; Klinfueng S; Sudhinaraset N; Mongkolsapaya J; Wanlapakorn N; Honsawek S; Poovorawan Y
Int J Infect Dis; 2022 Sep; 122():793-801. PubMed ID: 35863731
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and reactogenicity of repeated intradermal mRNA COVID-19 vaccines administered as a second booster dose in a Thai geriatric population.
Assantachai P; Niyomnaitham S; Toh ZQ; Thammasalee M; Pengsorn N; Monklang W; Licciardi PV; Chokephaibulkit K
Front Immunol; 2023; 14():1302041. PubMed ID: 38274835
[TBL] [Abstract][Full Text] [Related]
16. Humoral immune response after different SARS-CoV-2 vaccination regimens.
Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
[TBL] [Abstract][Full Text] [Related]
17. Detection of anti-SARS-CoV-2 salivary antibodies in vaccinated adults.
Castro VT; Chardin H; Amorim Dos Santos J; Barra GB; Castilho GR; Souza PM; Magalhães PO; Acevedo AC; Guerra ENS
Front Immunol; 2023; 14():1296603. PubMed ID: 38022522
[TBL] [Abstract][Full Text] [Related]
18. Comparison of anti-SARS-CoV-2 IgG and IgA antibody responses post complete vaccination, 7 months later and after 3rd dose of the BNT162b2 vaccine in healthy adults.
Rastawicki W; Juszczyk G; Gierczyński R; Zasada AA
J Clin Virol; 2022 Jul; 152():105193. PubMed ID: 35660747
[TBL] [Abstract][Full Text] [Related]
19. Durability of Immune Response After COVID-19 Booster Vaccination and Association With COVID-19 Omicron Infection.
Gilboa M; Regev-Yochay G; Mandelboim M; Indenbaum V; Asraf K; Fluss R; Amit S; Mendelson E; Doolman R; Afek A; Freedman LS; Kreiss Y; Lustig Y
JAMA Netw Open; 2022 Sep; 5(9):e2231778. PubMed ID: 36107426
[TBL] [Abstract][Full Text] [Related]
20. Kinetics of Neutralizing Antibodies against Omicron Variant in Vietnamese Healthcare Workers after Primary Immunization with ChAdOx1-S and Booster Immunization with BNT162b2.
Chau NVV; Nguyet LA; Dung NT; Quang VM; Truong NT; Toan LM; Hung LM; Man DNH; Khoa DB; Phong NT; Ngoc NM; Thao HP; Ty DTB; Thanh PB; Ny NTH; Thanh LK; Thuy CT; Anh NT; Hong NTT; Nhu LNT; Yen LM; Thwaites G; Thanh TT; Tan LV;
Am J Trop Med Hyg; 2023 Jan; 108(1):137-144. PubMed ID: 36450229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]